Metrifonate: A review of its use in Alzheimer's disease

CNS Drugs

Volumn 13, Issue 6, 2000, Pages 443-467

  Ormrod, Douglas ^a   Spencer, Caroline ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DICHLORVOS; DONEPEZIL; METRIFONATE; PHYSOSTIGMINE; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; ANTICHOLINERGIC EFFECT; BEHAVIOR; BRAIN FUNCTION; CLINICAL TRIAL; COGNITION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; LEG CRAMP; MEMORY; MUSCLE WEAKNESS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0034130555     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200013060-00006     Document Type: Review

References (85)

1. 1. Klysh AO. Alzheimer's disease update [online]. Available from: URL: http://www.inetce.org/Articles/alzheimers.html [Accessed: 1999 Oct 1]
2. 2. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997 Oct 22-29; 278: 1363-71
3. 3. Evans DA et al. Estimated prevalence of Alzheimer's disease in the United States. Milbank Quarterly 1990; 68 (2): 267-89
4. 4. Ernst RL, Hay JW. The U.S. economic and social cost of Alzheimer's disease revisited. Am J Public Health 1994; 84: 1261-4
5. 5. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA 1989; 262: 2551-6
6. 6. Carr DB, Goate PD, Morris JC. Current concepts in the pathogenesis of Alzheimer's disease. Am J Med 1997; 103 (3A): 3S-10S
7. 7. Stephenson J. Researchers find evidence of a new gene for late-onset Alzheimer disease. JAMA 1997; 277 (10): 755
8. 8. Small GW. Treatment of Alzheimer's disease: current approaches and promising developments. Am J Med 1998 Apr 27; 104: 32S-8S
9. 9. Ladner CJ, Lee JM. Pharmacological drug treatment of Alzheimer disease: the cholinergic hypothesis revisited. J Neuropathol Exp Neurol 1998; 57 (8): 719-31
10. 10. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983; 219: 1184-90
11. 11. Weinberger DR, Gibson R, Copploa R, et al. The distribution of cerebral muscarine acetylcholine receptors in vivo in patients with dementia. Arch Neurol 1991; 48: 169-76
12. 12. Andrews JS, Jansen JHM, Linders S, et al. Effects of disrupting the cholinergic system on short-term spatial memory in rats. Psychopharmacology 1994; 114:485-94
13. 13. Bymaster FP, Heath I, Hendrix JC, et al. Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. J Pharmacol Exp Ther 1993; 267: 16-24
14. 14. Ohno M, Yamamoto T, Watanabe S. Blockade of hippocampal M1 muscarine receptors impairs working memory performance of rats. Brain Res 1994; 650: 260-6
15. 15. Drachman DA, Leavitt J. Human memory and cholinergic system: a relationship to aging. Arch Neurol 1974; 30: 113-21
16. 16. Ukai M, Shinkai N, KameyamaT. Cholinergic receptor agonists inhibit pirenzepine-induced dysfunction of spontaneous alteration performance in the mouse. Gen Pharmacol 1995; 26 (7): 1529-32
17. 17. Jaen JC, Davis RE. Cholinergic therapies for Alzheimer's disease: acetylcholinesterase inhibitors of current clinical interest. Curr Opin Invest Drug 1993 Apr; 2: 363-77
18. 18. Lamy PP. The role of cholinesterase inhibitors in Alzheimer's disease. CNS Drugs 1994 Feb; 1: 146-65
19. 19. Little A, Levy R, Chuaqui-Kidd P, et al. A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985; 48 (8): 736-42
20. 20. Christie JE, Shering A, Ferguson J, et al. Physostigmine and arecoline: effects of intravenouis infusions in Alzheimer presenile dementia. Br J Psychiatry 1981; 138: 46-50
21. 21. Giacobini E. Invited review. Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications. Neurochem Int 1998; 32 (5-6): 413-9
22. 22. Jann MW. Preclinical pharmacology of metrifonate. Pharmaco-therapy 1998 Mar-Apr; 18 (2 Pt 2): 55S-67S
23. 23. Holmstedt B, Nordgren I, Sandoz M, et al. Metrifonate: summary of toxicological and pharmacological information available. Arch Toxicol 1978 Oct 13; 41: 3-29
24. 24. Mucke HAM. Metrifonate. Drugs Future 1998 May; 23: 491-7
25. 25. Hallak M, Giacobini E. A comparison of the effects of two inhibitors on brain cholinesterase. Neuropharmacology 1987; 26 (6): 521-30
26. 26. Hallak M, Giacobini E. Physostigmine, tacrine and metrifonate: The effect of multiple doses on acetylcholine metabolism in rat brain. Neuropharmacology 1989; 28 (3): 199-206
27. 27. Becker RE, Colliver J, Elble R, et al. Effects of metrifonate, a long-acting cholinesterase inhibitor, in Alzheimer disease: report of an open trial. Drug Dev Res 1990; 19 (4): 425-34
28. 28. Hinz VC, Blokland A, Van der Staay F-J, et al. Receptor interaction profile and CNS general pharmacology of metrifonate and its transformation product dichlorvos in rodents. Drug Dev Res 1996; 38 (1): 31-42
29. 29. Hinz VC, Grewig S, Schmidt BH. Metrifonate induces cholinesterase inhibition exclusively via slow release of dichlorvos. Neurochem Res 1996 Mar; 21: 331-7
30. 30. Hofer W. Chemistry of metrifonate and dichlorvos. Acta Pharmacol Toxicol 1981; 49 Suppl V: 7-14
31. 31. Pacheco G, Palacios Esquivel R, Moss DE. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase. J Pharmacol Exp Ther 1995 Aug; 274: 767-70
32. 32. Mesulam M-M, Geula C. Cortical cholesterinases in Alzheimer's disease: anatomical and enzymatic shifts from the normal pattern. In: Becker R, Giacobini E, editors. Cholinergic basis for Alzheimer therapy. Boston (MA): Birkhauser, 1991: 25-30
33. 33. Rosenberry TL, Roberts WL, Hass R. Glycolipid membrane binding of human erthrocyte acetylcholinesterase. Fed Proc 1986; 45: 2970-5
34. 34. Moriearty PL, Becker RE. Inhibition of human brain and red blood cell acetylcholinesterase (AChE) by heptylphysostigmine. Methods Find Exp Clin Pharmacol 1992; 14: 615-21
35. 35. Siek GC, Katz LS, Fishman EB. et al. Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain. Biol Psychiatry 1990; 27: 573-80
36. 36. Younkin SG, Goodridge B, Katz J, et al. Molecular forms of acetylcholinesterasc in Alzheimer's disease. Fed Proc 1986; 45: 2982-8
37. 37. Fishman EB, Siek GC, MacCallum RD, et al. Distribution of the molecular forms of acetylcholinesterase in human brain: alterations in dementia of the Alzheimer type. Ann Neurol 1986; 19: 246-52
38. 38. Ogane N, Giacobini E, Messamore E. Preferential inhibition of acetylcholinesterase molecular forms in rat brain. Neurochem Res 1992 May; 17: 489-95
39. 39. Giovannini MG, Scali C, Bartolini L, et al. Effect of subchronic treatment with metrifonate and tacrine on brain cholinergic function in aged F344 rats. Eur J Pharmacol 1998 Jul 31; 354: 17-24
40. 40. Scali C, Giovannini MG, Bartolini L, et al. Effect of metrifonate on extracellular brain acetylcholine and object recognition in aged rats. Eur J Pharmacol 1997 May 1; 325: 173-80
41. 41. Mori F, Cuadra G, Giacobini E. Metrifonate effects on acetylcholine and biogenic amines in rat cortex. Neurochem Res 1995 Sep; 20: 1081-8
42. 42. Heinig R, Versavel M, Breuel HP, et al. Rapid attainment of steady-state acetylcholinesterase inhibition by administration of metrifonate loading and maintenance doses once-daily in elderly volunteers [abstract no. 39-26]. Biol Psychiatry 1997 Jul; 42 Suppl.: 94S
43. 43. Aden-Abdi Y, Villen T, Ericsson O, et al. Metrifonate in healthy volunteers = interrelationship between pharmacokinetic properties, cholinesterase inhibition and side-effects. Bull World Health Organ 1990; 68 (6): 731-6
44. 44. Pettigrew LC, Bieber F, Lettieri J, et al. Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease. J Clin Pharmacol 1998 Mar; 38: 236-45
45. 45. Riekkinen Jr P, Schmidt B, Stefanski R, et al. Metrifonate improves spatial navigation and avoidance behavior in scopolamine-treated, medial septum-lesioned and aged rats. Eur J Pharmacol 1996 Aug 8; 309: 121-30
46. 46. Itoh A, Nitta A, Katono Y, et al. Effects of metrifonate on memory impairment and cholinergic dysfunction in rats. Eur J Pharmacol 1997 Mar 12; 322: 11-9
47. 47. van der Staay FJ, Hinz VC, Schmidt BH. Effects of metrifonate on escape and avoidance learning in young and aged rats. Behav Pharmacol 1996 Jan; 7: 56-64
48. 48. van der Staay FJ, Hinz VC, Schmidt BH. Effects of metrifonate, its transformation product dichlorvos, and other organophosphorus and reference cholinesterase inhibitors on Morris water escape behavior in young-adult rats. J Pharmacol Exp Ther 1996 Aug; 278: 697-708
49. 49. Blokland A, Hinz V, Schmidt BH. Effects of metrifonate and tacrine in the spatial Morris task and modified Irwin tesl: evaluation of the efficacy/safety profile in rats. Drug Dev Res 1995 Dec; 36: 166-79
50. 50. Aden-Abdi YA, Villen T. Pharmacokinetics of metrifonate and its rearrangement product dichlorvos in whole blood. Pharmacol Toxicol 1991 Feb; 68: 137-9
51. 51. Unni LK, Womack C, Hannant ME, et al. Pharmacokinetics and pharmacodynamics of metrifonate in humans. Methods Find Exp Clin Pharmacnl 1994 May; 16: 285-9
52. 52. Dingemanse J, Halabi A, Kleinbloesem CH, et al. Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor metrifonate in patients with renal impairment. Ther Drug Monit 1999 Jun; 21: 310-6
53. 53. Villén T, Aden Abdi Y, Ericsson Ö, et al. Analysis of metrifonate and diclorvos in whole blood using gas chromatography and gas chromatography mass spectrometry. J Chromatogr 1990; 529 (2): 309-17
54. 54. Heinig R, Dietrich H, Halabi A. Pharmacokinetics of metrifonate and its metabolite dichlorvos in healthy volunteers and in patients with renal impairment. Clin Drug Invest 1999 Jul; 18; 35-46
55. 55. World Health Organization. Trichlorfon. Environmental Health Criteria 132. World Health Organization, Geneva, 1992
56. 56. Heinig R, Sachse R. The effect of food and time of administration on the pharmacokinetic and pharmacodynamic profile of metrifonate. Int J Clin Pharmacol Ther 1999; 37 (9): 456-64
57. 57. Becker RE, Colliver JA, Markwell SJ, et al. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease. Alz Dis Assoc Disord 1996; 10 (3): 124-31
58. 58. Becker RE, Colliver JA, Markwell SJ, et al. Effects of metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-controlled, 6-month study. Alz Dis Assoc Disord 1998 Mar; 12: 54-7
59. 59. Cummings JL, Cyrus PA, Bieber F, et al. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology 1998 May; 50: 1214-21
60. 60. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998 May; 50: 1222-30
61. 61. Raskind MA, Cyrus PA, Ruzicka BB, et al. The effecls of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. J Clin Psychiatry 1999 May; 60: 318-25
62. 62. Dubois B, McKeith, Orgogozo J-M, et al. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study. Int J Geriatr Psychiatry 1999; 14 (11): 973-82
63. 63. Jann MW, Cyrus PA, Eisner LS, et al. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Clin Ther 1999 Jan; 21: 88-102
64. 64. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-44
65. 65. American Psychiatric Association. Diagnosis and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
66. 66. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state" a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98
67. 67. Rosen WG, Terry RD, Fuld P, et al. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980; 7: 486-8
68. 68. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141 (11); 1356-64
69. 69. Knopman DS, Knapp MJ, Gracon SI, et al. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Am J Psychiatry 1994; 44: 2315-21
70. 70. Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14
71. 71. Reisberg B, Ferris S, De Leon MJ, et al. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139 (9): 1136-9
72. 72. Gauthier S, Gélinas I, Gauthier L. Functional disability in Alzheimer's disease. Int Psychogeriatr 1997; 9 Suppl. 1: 163-5
73. 73. Shikiar R, Shakespeare A, Sagnier P-P, et al. The impact of metrifonate therapy on caregivers of patients with Alzheimer's disease: results from the MALT clinical trial. J Am Geriatr Soc 2000; 48: 268-74
74. 74. Farlow MR, Cyrus PA. Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double blind, placebo-controlled trials. Dementia Geriatr Cogn Disord 2000. In press
75. 75. Cyrus P, Camicioli R, Kaye J. Patients with Alzheimer's disease benefit from metrifonate treatment regardless of their demographic characteristics and previous cholinesterase therapy [abstract]. Neurology 1999 Apr 12; 52 Suppl. 2: A482
76. 76. Forchetti C, Cyrus P. Metrifonate improves cognitive performance in patients with Alzheimer's disease despite concurrent mild ischemic damage [abstract]. Neurology 1999 Apr 12; 52 Suppl. 2: A173
77. 77. Bayer halts trial on new Alzheimer's drug. Pharm J 1998 Oct 10; 261: 561
78. 78. Blass JP, Cyrus PA, Bieber F, et al. A randomized, double blind, placebo-controlled, multi-center study to evaluate the safety and tolerability of metrifonate in patients with probable Alzheimer disease. Alz Dis Assoc Disord 2000; 14 (1): 39-41
79. 79. Cyrus PA, Ruzicka B, Gulanski B. Metrifonate in the long-term treatment of Alzheimer's disease [abstract]. J Am Geriatr Soc 1998 Sep; 46: S35
80. 80. Steinberg M. Pharmacologic treatment of Alzheimer's disease: an update on approved, unapproved therapies. Formulary 1999 Jan; 34: 32-44
81. 81. Becker RE, Giacobini E. Pharmacokinetics and pharmacodynamics of acetylcholinesterase inhibition: can acetylcholine levels in the brain be improved in Alzheimer's disease? Drug Dev Res 1988; 14 (3-4): 235-46
82. 82. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994 Apr: 271 (13): 985-91
83. 83. Dooley M, Lamb H. Donepezil: A review of its use in Alzheimers's disease. Drugs Aging 2000; 16 (3): 199-226
84. 84. Spencer CM, Noble S. Rivastigmine: a review of its use in Alzheimer's disease. Drugs Aging 1998 Nov; 13: 391-410
85. 85. Knopman DS. Metrifonate for Alzheimer's disease. Is the next cholinesterase inhibitor better [abstract]? Neurology 1998 May; 50: 1203-5